Long-term Safety of GnRHa Affirmed in Premenopausal Women Undergoing Chemo for Breast Cancer

In premenopausal women with early breast cancer, use of a gonadotropin-releasing hormone agonist during chemotherapy did not increase the risk of cancer recurrence for up to 12 years, according to the PROMISE-GIM6 trial.

Related Keywords

New York ,United States ,Italy ,Columbia University ,Italian ,Neil Vasan ,N Lynn Henry ,University Of Genova ,Reuters Health ,University Of Michigan Rogel Cancer Center ,Journal Of The National Cancer Institute ,Columbia University Medical Center ,National Cancer Institute ,Lucia Del Mastro ,Del Mastro ,Disease Lead ,Breast Oncology ,Michigan Rogel Cancer Center ,Ann Arbor ,Herbert Irving Comprehensive Cancer Center ,New York City ,Katherine Crew ,Breast Cancer ,Alignant Breast Neoplasm ,Breast Carcinoma ,Chemotherapy ,Cancer ,Alignant Neoplasia ,Arcinoma ,Alignant Neoplasm ,Breast ,Mammary Gland ,Menopause ,Menopausal Syndrome ,Adjuvant Chemotherapy ,Clinical Research ,Clinical Trials ,Linical Studies ,Cancer Risk ,Gnrh Agonists ,Gonadotropin Releasing Hormone Agonists ,Nrh A ,Adverse Effects ,Side Effects ,Ovarian Insufficiency ,